Diagnosing and Treating Inflammatory Diseases
AssigneeTla Targeted Immunotherapies AB
InventorsOla Winqvist, Graham Cotton
Life of this patent
Estimating the term…
Abstract
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease. Similar methods for diagnosing irritable bowel syndrome are also described. Various companion therapeutic methods and useful binding reagents are also described.
Claims58
A method for treating inflammatory bowel disease comprising:
- applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a marker of CD14+HLA-DRhi monocytes selected from CD14, CCR7 and CCR9, wherein the one or more binding reagents are immobilized directly or indirectly on the support thus removing CD14+HLA-DRhi monocytes from the peripheral blood of the patient;
- and
- returning the peripheral blood from which CD14+HLA-DRhi monocytes are removed to the patient.
A method for treating IBS comprising:
- applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR9 immobilized directly or indirectly on the support thus removing chemokine receptor cells, optionally CCR9 expressing cells, from the peripheral blood of the patient.
A modified CCL19 chemokine comprising the amino acid sequence of SEQ ID NO:
- 4 or SEQ ID NO:
- 6.
An apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a marker of CD14+HLA-DRhi monocytes, wherein the one or more binding reagents are immobilized directly or indirectly on the support to permit removal of a cell expressing the chemokine receptor from the peripheral blood of a patient, wherein the binding reagent is not a chemokine.
A binding reagent capable of specifically binding to a marker of CD14+HLA-DRhi monocytes selected from CD14, CCR7 and CCR9 for use in the treatment of inflammatory bowel disease, wherein the binding reagent is immobilized on a solid support contained within an apheresis column, to which is applied peripheral blood from a patient thus removing CD14+HLA-DRhi monocytes from the peripheral blood of the patient or subject.
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprising:
- determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease.
A method of diagnosing, monitoring progression of, or monitoring treatment of IBS comprising determining:
- a) the levels of CCR9 expressing cells, particularly levels of CCR9 expressing monocytes
- b) levels of expression of CCR9;
- and/or
- c) levels of cells with high expression of CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing, high levels of expression of CCR9 or high levels of cells with high expression of CCR9 or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR9 compared to control, increased levels of expression of CCR9 compared to a control or increased levels of cells with high expression of CCR9 compared to a control indicate the presence or progression of IBS.
A method of selecting a suitable treatment for inflammatory bowel disease comprising determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, result in selection of corticosteroid treatment or a monocyte reduction therapy for treatment of the inflammatory bowel disease.
A method for treating an inflammatory condition comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, immobilized directly or indirectly on the support thus removing one or more chemokine receptor expressing cells from the peripheral blood of the patient or subject.
Dependencies are inferred from the claim text.